Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINALITY-HF
2023-508875-35-00Phase 3Authorised
- Sponsor
- CPC Clinical Research
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Finerenone with Placebo (2 arms). Planned start Sep 2025; status: authorised.
02
Drugs
finerenone
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-508875-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508875-35-00.